awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34029999-CA8B3898-D73C-4205-8732-FCDD48887128
Q34029999-CA8B3898-D73C-4205-8732-FCDD48887128
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34029999-CA8B3898-D73C-4205-8732-FCDD48887128
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
P2860
Q34029999-CA8B3898-D73C-4205-8732-FCDD48887128
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34029999-CA8B3898-D73C-4205-8732-FCDD48887128
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1eda9ffa83d190ef12cd578122dabd8aad4ebf3e
P2860
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.